Search research articles
Contact Us
Filters
Showing results (21-30 of 64) with videos related to
Page
of 7
Sort By:
The Indian Journal of Medical Research
|
April 27, 2010
Hypophosphataemic rickets/osteomalacia: a descriptive analysis
S K Bhadada, A Bhansali, V Upreti, et al.
Toxicology Letters
|
May 19, 2009
Drug interaction between ethanol and 3,4-methylenedioxymethamphetamine ("ecstasy")
Vijay V Upreti, Natalie D Eddington, Kwan-Hoon Moon, et al.
Current Pharmaceutical Biotechnology
|
April 28, 2010
Mechanisms of MDMA (ecstasy)-induced oxidative stress, mitochondrial dysfunction, and organ damage
Byoung-Joon Song, Kwan-Hoon Moon, Vijay V Upreti, et al.
BMJ Case Reports
|
July 14, 2012
A child with suprasellar mass and ascites
S Das, A Bhansali, V Upreti, et al.
Journal of Pharmaceutical Sciences
|
February 16, 2012
Biowaiver approach for biopharmaceutics classification system class 3 compound metformin hydrochloride using in silico modeling
John R Crison, Peter Timmins, Anther Keung, et al.
Journal of Clinical Pharmacology
|
March 26, 2019
The Potential Role of the J-T<sub>peak</sub> Interval in Proarrhythmic Cardiac Safety: Current State of the Science From the American College of Clinical Pharmacology and the Cardiac Safety Research Consortium
Jose Vicente, David G Strauss, Vijay V Upreti, et al.
Diabetes, Obesity & Metabolism
|
July 11, 2012
Effect of saxagliptin on the pharmacokinetics of the active components of Ortho-Cyclen(®), a combined oral contraceptive containing ethinyl estradiol and norgestimate, in healthy women
V V Upreti, C B Hsiang, L Li, et al.
Clinical Pharmacokinetics
|
April 18, 2023
Mechanistic Pharmacokinetic/Pharmacodynamic Modeling in Support of a Patient-Convenient, Longer Dosing Interval for Carfilzomib, a Covalent Inhibitor of the Proteasome
Marc R Yago, Khamir Mehta, Maitreyee Bose, et al.
British Journal of Clinical Pharmacology
|
June 10, 2011
Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects
Vijay V Upreti, David W Boulton, Li Li, et al.
Journal of Clinical Pharmacology
|
September 11, 2023
Clinical Pharmacology Profile of AMG 119, the First Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting Delta-Like Ligand 3 (DLL3), in Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC)
Di Zhou, Lauren A Byers, Beate Sable, et al.
Page
of 7
Search research articles
Search
Showing results (21-30 of 64) with videos related to
Sort By:
Page
of 7
The Indian Journal of Medical Research
|
April 27, 2010
Hypophosphataemic rickets/osteomalacia: a descriptive analysis
S K Bhadada, A Bhansali, V Upreti, et al.
Toxicology Letters
|
May 19, 2009
Drug interaction between ethanol and 3,4-methylenedioxymethamphetamine ("ecstasy")
Vijay V Upreti, Natalie D Eddington, Kwan-Hoon Moon, et al.
Current Pharmaceutical Biotechnology
|
April 28, 2010
Mechanisms of MDMA (ecstasy)-induced oxidative stress, mitochondrial dysfunction, and organ damage
Byoung-Joon Song, Kwan-Hoon Moon, Vijay V Upreti, et al.
BMJ Case Reports
|
July 14, 2012
A child with suprasellar mass and ascites
S Das, A Bhansali, V Upreti, et al.
Journal of Pharmaceutical Sciences
|
February 16, 2012
Biowaiver approach for biopharmaceutics classification system class 3 compound metformin hydrochloride using in silico modeling
John R Crison, Peter Timmins, Anther Keung, et al.
Journal of Clinical Pharmacology
|
March 26, 2019
The Potential Role of the J-T<sub>peak</sub> Interval in Proarrhythmic Cardiac Safety: Current State of the Science From the American College of Clinical Pharmacology and the Cardiac Safety Research Consortium
Jose Vicente, David G Strauss, Vijay V Upreti, et al.
Diabetes, Obesity & Metabolism
|
July 11, 2012
Effect of saxagliptin on the pharmacokinetics of the active components of Ortho-Cyclen(®), a combined oral contraceptive containing ethinyl estradiol and norgestimate, in healthy women
V V Upreti, C B Hsiang, L Li, et al.
Clinical Pharmacokinetics
|
April 18, 2023
Mechanistic Pharmacokinetic/Pharmacodynamic Modeling in Support of a Patient-Convenient, Longer Dosing Interval for Carfilzomib, a Covalent Inhibitor of the Proteasome
Marc R Yago, Khamir Mehta, Maitreyee Bose, et al.
British Journal of Clinical Pharmacology
|
June 10, 2011
Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects
Vijay V Upreti, David W Boulton, Li Li, et al.
Journal of Clinical Pharmacology
|
September 11, 2023
Clinical Pharmacology Profile of AMG 119, the First Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting Delta-Like Ligand 3 (DLL3), in Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC)
Di Zhou, Lauren A Byers, Beate Sable, et al.
Page
of 7